Abeona Therapeutics® And Children’s Hospital Colorado Launch Newest Treatment Center For ZEVASKYN® Gene Therapy

Abeona Therapeutics Inc. and Children’s Hospital Colorado have announced the activation of Children’s Colorado as the newest Qualified Treatment Center (QTC) for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first FDA-approved therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). With the completion of QTC start-up activities, Children’s Colorado in Aurora, CO, can now begin identifying patients and scheduling ZEVASKYN treatments.

Children’s Colorado is recognized as a center of excellence for epidermolysis bullosa (EB) by debra of America, the leading patient advocacy organization for EB. The hospital is also a member of the EB Clinical Research Consortium and conducts advanced bench and clinical research aimed at developing innovative treatments for rare diseases, offering hope for transformative care and improved quality of life for patients with EB. The Precision Medicine Institute at Children’s Colorado supports these efforts by using patients’ unique genetic information to guide novel therapies like ZEVASKYN.

Anna L. Bruckner, MD, Co-Director of the EB Clinic at Children’s Hospital of Colorado and Professor of Dermatology, University of Colorado School of Medicine, said in a statement, “We are thrilled to be able to provide our patients a much needed, long lasting treatment option, and with it, the hope for an improved quality of life.”

Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona, stated, “We are excited to be working with Dr. Bruckner and Children's Hospital Colorado in making ZEVASKYN available to RDEB patients. Dr. Bruckner is one of the leading experts in EB care, and the activation of Children’s Colorado is a major milestone in broadening access to ZEVASKYN across a growing network of established EB centers.”

Patients and caregivers seeking information on accessing ZEVASKYN or learning about support services can visit www.abeonaassist.com

, call 1-855-ABEONA-1 (1-855-223-6621), or email MyNavigator@AbeonaAssist.com

. Abeona Assist™, the company’s comprehensive patient support program, provides personalized assistance, including guidance on insurance coverage, financial support options, and travel and logistical arrangements for treatment.